KdT Ventures, an Austin, Texas-based early-stage frontier science venture capital firm, closed its second fund, at $50m.
Fund II will focus broady on science which includes areas such as gene and biological circuit fabrication, novel delivery technologies, biomaterials innovation, and consumer biology. KdT has already deployed capital from Fund II in several investments including Elegen, Xilis, STRM, Abridge, Dimension Inx, and Andes.
Founded in 2017 by Cain McClary, KdT Ventures invests in companies applying computation to chemical and biological systems. The $15M inaugural fund enabled the firm to make 18 investments in early-stage science companies at the intersection of data, engineering, and biology including: PathAI, 54Gene, Checkerspot, Dyno Therapeutics, Terray and Solugen.
The firm has offices in Houston, TX and Raleigh-Durham, NC.